Table 1.
Baseline demographic and clinical characteristics.
Fig 1.
Measures of alpha-diversity (Shannon Index and number (#) of observed operationalized taxonomic units (ESVs)) by ≤ vs. > median weight adjusted TAC dose (1A and 1B) and by ≤ vs. > median Level/Dose (L/D) ratio (1C and 1D).
Fig 2.
Principle coordinates, derived from the Bray-Curtis dissimilarity index, plotted according to ≤ vs. > median weight adjusted TAC dose (left) and ≤ vs. > median Level/Dose (L/D) ratio (right). Ellipses represent a 95% confidence interval for the data, assuming a normal distribution.
Fig 3.
Top: Relative abundance of phyla per sample in ≤ vs > median weight adjusted TAC dose. Bottom: phyla composition by sample. No statistically significant difference was observed in phyla relative abundance by TAC dose group.
Fig 4.
Firmicutes to Bacteroidetes ratio (using rarefied data) by TAC group.
There is no statistical significance (p-value = 0.76) and the mean values are similar (165 and 188, respectively).
Fig 5.
Stacked bar chart showing relative abundance of ESVs observed to be statistically significantly different between patients with ≤ vs. > median weight adjusted TAC dose.
Taxa shown signififcantly differed in both adjusted and unadjusted analyses. Segments within a stack correspond to a single ESV and are colored according to genera. ESVs that did not significantly differ between TAC dose group are not displayed.
Table 2.
Biomarkers of endotoxemia (LPS), inflammation(TNF-alpha) and oxidative stress (isoprostane) by tacrolimus dosing requirements.
Table 3.
Correlation between Shannon index and number of observed ESVs (alpha diversity metrics) and biomarkers of inflammation, endotoxemia and oxidative stress.